Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 9.75 Billion KRW | -73.64% |
| 2022 | 37 Billion KRW | -60.69% |
| 2021 | 94.15 Billion KRW | 418.34% |
| 2020 | -29.57 Billion KRW | -212.86% |
| 2019 | 26.2 Billion KRW | -62.54% |
| 2018 | 69.96 Billion KRW | -0.2% |
| 2017 | 70.1 Billion KRW | 18.36% |
| 2016 | 59.23 Billion KRW | 40.05% |
| 2015 | 42.29 Billion KRW | -3.06% |
| 2014 | 43.62 Billion KRW | 205.01% |
| 2013 | 14.3 Billion KRW | -7.34% |
| 2012 | 15.43 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.46 Billion KRW | 28.25% |
| 2024 Q2 | 11.41 Billion KRW | 876.43% |
| 2023 Q2 | 8.56 Billion KRW | 54.06% |
| 2023 FY | 9.75 Billion KRW | -73.64% |
| 2023 Q4 | -2.04 Billion KRW | 11.8% |
| 2023 Q1 | 5.55 Billion KRW | 1254.15% |
| 2023 Q3 | -2.32 Billion KRW | -127.11% |
| 2022 Q3 | 13.2 Billion KRW | -31.33% |
| 2022 FY | 37 Billion KRW | -60.69% |
| 2022 Q4 | -481.73 Million KRW | -103.65% |
| 2022 Q2 | 19.23 Billion KRW | 280.93% |
| 2022 Q1 | 5.04 Billion KRW | 137.96% |
| 2021 FY | 94.15 Billion KRW | 418.34% |
| 2021 Q1 | 55.17 Billion KRW | 411.23% |
| 2021 Q2 | 31.65 Billion KRW | -42.63% |
| 2021 Q3 | 20.62 Billion KRW | -34.84% |
| 2021 Q4 | -13.3 Billion KRW | -164.49% |
| 2020 Q3 | -43.75 Million KRW | 99.26% |
| 2020 Q4 | -17.72 Billion KRW | -40414.68% |
| 2020 FY | -29.57 Billion KRW | -212.86% |
| 2020 Q2 | -5.9 Billion KRW | 0.03% |
| 2020 Q1 | -5.9 Billion KRW | -474.45% |
| 2019 FY | 26.2 Billion KRW | -62.54% |
| 2019 Q1 | 13.63 Billion KRW | -16.61% |
| 2019 Q2 | 10.5 Billion KRW | -22.9% |
| 2019 Q4 | -1.02 Billion KRW | -133.22% |
| 2019 Q3 | 3.09 Billion KRW | -70.56% |
| 2018 Q4 | 16.34 Billion KRW | 13.39% |
| 2018 FY | 69.96 Billion KRW | -0.2% |
| 2018 Q3 | 14.41 Billion KRW | -19.74% |
| 2018 Q2 | 17.95 Billion KRW | -15.47% |
| 2018 Q1 | 21.24 Billion KRW | 9.75% |
| 2017 Q3 | 13.28 Billion KRW | -35.25% |
| 2017 Q1 | 16.95 Billion KRW | 12.54% |
| 2017 Q2 | 20.5 Billion KRW | 20.94% |
| 2017 Q4 | 19.35 Billion KRW | 45.77% |
| 2017 FY | 70.1 Billion KRW | 18.36% |
| 2016 Q4 | 15.06 Billion KRW | 3.17% |
| 2016 Q3 | 14.6 Billion KRW | -8.37% |
| 2016 Q2 | 15.94 Billion KRW | 17.07% |
| 2016 Q1 | 13.61 Billion KRW | 18.46% |
| 2016 FY | 59.23 Billion KRW | 40.05% |
| 2015 Q2 | 11.77 Billion KRW | 37.8% |
| 2015 Q1 | 8.54 Billion KRW | 29.55% |
| 2015 Q4 | 11.49 Billion KRW | 9.61% |
| 2015 Q3 | 10.48 Billion KRW | -10.92% |
| 2015 FY | 42.29 Billion KRW | -3.06% |
| 2014 Q1 | 6.56 Billion KRW | 57.66% |
| 2014 Q4 | 6.59 Billion KRW | -69.78% |
| 2014 Q2 | 8.64 Billion KRW | 31.64% |
| 2014 Q3 | 21.82 Billion KRW | 152.37% |
| 2014 FY | 43.62 Billion KRW | 205.01% |
| 2013 Q2 | 4.12 Billion KRW | 68.26% |
| 2013 Q4 | 4.16 Billion KRW | 17.1% |
| 2013 FY | 14.3 Billion KRW | -7.34% |
| 2013 Q1 | 2.45 Billion KRW | -32.32% |
| 2013 Q3 | 3.55 Billion KRW | -13.8% |
| 2012 FY | 15.43 Billion KRW | 0.0% |
| 2012 Q4 | 3.62 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 105.159% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | 200.616% |
| BINEX Co., Ltd. | 4.67 Billion KRW | -108.855% |
| Bioneer Corporation | -10.58 Billion KRW | 192.142% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | 443.387% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | -67.039% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 119.939% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 115.221% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | 215.702% |
| Peptron, Inc. | -15.92 Billion KRW | 161.269% |
| Amicogen, Inc. | -23.28 Billion KRW | 141.887% |
| Genexine, Inc. | -66.87 Billion KRW | 114.587% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | 523.737% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 113.236% |
| ALTEOGEN Inc. | -3.37 Billion KRW | 389.317% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 87.257% |
| SillaJen, Inc. | -20.36 Billion KRW | 147.891% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 30.151% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 151.069% |
| Genomictree Inc. | -8.75 Billion KRW | 211.41% |
| MedPacto, Inc. | -35.32 Billion KRW | 127.615% |
| D&D Pharmatech | 3.93 Billion KRW | -147.981% |
| EASY BIO,Inc. | 15.54 Billion KRW | 37.241% |
| GI Innovation, Inc. | -55.49 Billion KRW | 117.578% |